ABIONYX PHARMA
ABIONYX Pharma is a biotech company discovering and developing innovative therapies for patients without existing or effective treatment.
ABIONYX PHARMA
Industry:
Biotechnology Health Care
Founded:
2005-01-01
Address:
Balma, Midi-Pyrenees, France
Country:
France
Website Url:
http://www.abionyx.com
Total Employee:
11+
Status:
Active
Contact:
33 5 62 24 97 06
Email Addresses:
[email protected]
Total Funding:
154.16 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Universal Analytics Nginx Cloudflare JS
Current Advisors List
Current Employees Featured
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-11-17 | Iris Pharma | Iris Pharma acquired by Abionyx Pharma | 5 M EUR |
Investors List
IXO Private Equity
IXO Private Equity investment in Series C - Abionyx Pharma
TVM Capital
TVM Capital investment in Series C - Abionyx Pharma
Fonds Stratégique d'Investissement
Fonds Stratégique d'Investissement investment in Series C - Abionyx Pharma
Daiwa Corporate Investment
Daiwa Corporate Investment investment in Series C - Abionyx Pharma
OrbiMed
OrbiMed investment in Series C - Abionyx Pharma
EDF Ventures
EDF Ventures investment in Series C - Abionyx Pharma
HealthCap
HealthCap investment in Series C - Abionyx Pharma
Alta Partners
Alta Partners investment in Series C - Abionyx Pharma
IRDI
IRDI investment in Series C - Abionyx Pharma
Sofinnova Partners
Sofinnova Partners investment in Series C - Abionyx Pharma
Official Site Inspections
http://www.abionyx.com Semrush global rank: 7.06 M Semrush visits lastest month: 614
- Host name: srvz2.ericzapata.com
- IP address: 87.98.137.5
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "Abionyx Pharma"
Abionyx Pharma - Crunchbase Company Profile
AbIONYX Pharma is a biotechnology company that is focused on providing innovative therapies for indications without effective or existing treatments, …See details»
Abionyx Pharma - Funding, Financials, Valuation & Investors
Nov 17, 2021 Abionyx Pharma is registered under the ticker EPA:ABNX . Abionyx Pharma is funded by 13 investors. France 2030 and Bpifrance are the most recent investors. Abionyx …See details»
Abionyx Pharma SA, 609:DUS profile - FT.com - Financial Times
5 days ago Year on year Abionyx Pharma SA 's net income fell 25.07% from a loss of 3.52m to a larger loss of 4.40m despite flat revenues. A contributing factor has been an increase in the …See details»
ABIONYX Pharma SA (ABNX.PA) company profile & facts - Yahoo …
See the company profile for ABIONYX Pharma SA (ABNX.PA), including business summary, industry/sector information, number of employees, corporate governance, key executives and …See details»
News at Abionyx - The Official Board
Abionyx has 2,345 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Biogen (United States (USA)). Popular M&A news in Biotechnology Purespring Therapeutics has just …See details»
Abionyx - VentureRadar
ABIONYX Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The …See details»
Abionyx : Biotech de nouvelle génération - Mentions légales
Le site Internet www.abionyx.com est la propriété de ABIONYX Pharma SA, 33 43 av. Georges Pompidou Bât. D2 - 31130 Balma France immatriculée au RCS sous le numéro 481 637 718. …See details»
Abionyx : A new generation biotech company - Abionyx - Financial …
7 rows Feb 27, 2025 Events: Dates: Cash position and activity update for Q4 2024: Thursday, February 27, 2025: 2024 Full-Year Results: Thursday, March 6, 2025: Cash position and …See details»
Organigramme Abionyx - The Official Board
Abionyx a 9 dirigeants. Abionyx; Merci de confirmer la suppression . Supprimer ou Annuler . Désolé, vous n'avez plus de crédit pour voir cet organigramme. Pour poursuivre, vous pouvez …See details»
ABIONYX Pharma Provides an Update on Its Business and Cash …
Dec 31, 2024 Consolidated revenue of €4.6m in 2024; Available cash of €3.2m at December 31, 2024; Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA PME), …See details»
ABIONYX Pharma Provides Further Details on the Setting up of Its …
May 29, 2023 TOULOUSE, France & LAKELAND, Mich., May 29, 2023--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible) (Paris:ABNX), a new …See details»
ABIONYX Pharma: Monthly Statement of Total Voting Rights and …
Mar 4, 2025 ABIONYX Pharma is a next-generation biotech company focused on developing innovative medicines in diseases where there is no effective or existing treatment, even the …See details»
ABIONYX Pharma fait le point sur son activité et sa position de ...
Feb 28, 2023 Regulatory News: ABIONYX Pharma, (FR0012616852 – ABNX – éligible PEA PME) (Paris:ABNX), société biotech de nouvelle génération dédiée à la découverte et au …See details»
Résultats annuels 2021 - abionyx.com
Toulouse, FRANCE, Lakeland, ETATS-UNIS, 28 avril 2022, 18h – ABIONYX Pharma, (FR0012616852 – ABNX – éligible PEA PME), société biotech de nouvelle génération dédiée …See details»
CER-002 (Cerenis) - Life-Sciences-Europe.com
BIO (US) (Biotechnology Innovation Organization, formerly Biotechnology Industry Organization) EuropaBio aisbl – the European Association of Bioindustries; BioIndustry Association (BIA) …See details»
ABNX Dividends - Abionyx Pharma SA - Alpha Spread
Detailed information on Abionyx Pharma SA (PAR:ABNX) dividends, shareholder yield, buybacks, and debt paydown yield.See details»
ABIONYX Pharma announces its strategy in ophthalmology and …
ABIONYX Pharma's most advanced drug candidate in ophthalmology, CER-001, targeting Fish-Eye Diseas in LCAT Deficiency, is currently being used under compassionate approval in …See details»
Abionyx Pharma reçoit une aide à l’innovation d’environ 1 million …
Mar 15, 2024 Abionyx Pharma, société biotech de nouvelle génération dédiée à la découverte et au développement de thérapies innovantes basées sur la seule apoA-I naturelle recombinante …See details»
Abionyx : A new generation biotech company - Bpifrance supports …
ABIONYX plans to explore joint activities with attractive partners. Abionyx : A new generation biotech company - Bpifrance supports the clinical development of CER-209 in NAFLD /NASH …See details»